Leerink Partners analyst David Risinger reiterated a Market Perform rating and $10.00 price target on Theravance Biopharma (NASDAQ: TBPH).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form SC 13G/A Theravance Biopharma, Filed by: VANGUARD GROUP INCNovember 12, 2024 5:53 PM Theravance Biopharma (TBPH) Misses Q3 EPS by 3c, provides guidanceNovember 12, 2024 4:11 PM Form 8-K Theravance Biopharma, For: Nov 12November 12, 2024 4:09 PM Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValueNovember 12, 2024 4:05 PM